DK2327765T3 - Nitrilaser - Google Patents

Nitrilaser Download PDF

Info

Publication number
DK2327765T3
DK2327765T3 DK10189100.0T DK10189100T DK2327765T3 DK 2327765 T3 DK2327765 T3 DK 2327765T3 DK 10189100 T DK10189100 T DK 10189100T DK 2327765 T3 DK2327765 T3 DK 2327765T3
Authority
DK
Denmark
Prior art keywords
acid
sequence
polypeptide
sequences
nucleic acid
Prior art date
Application number
DK10189100.0T
Other languages
English (en)
Inventor
Jennifer Ann Chaplin
David Paul Weiner
Aileen Milan
Ellen Chi
Jay M Short
Mark Madden
Mark Burk
Dan Robertson
Grace Desantis
Original Assignee
Basf Enzymes Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Enzymes Llc filed Critical Basf Enzymes Llc
Application granted granted Critical
Publication of DK2327765T3 publication Critical patent/DK2327765T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/002—Nitriles (-CN)
    • C12P13/004—Cyanohydrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Treatment Of Sludge (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Processing Of Solid Wastes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Claims (17)

1. Isoleret, syntetisk eller rekombinant nukleinsyre indeholdende (a) en nukleinsyresekvens, der har mindst 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% eller mere, eller 100% sekvensidentitet med SEQ ID NO: 103 og kodende for et polypeptid med nitrilaseaktivitet, hvor nukleinsyren koder for mindst ét polypeptid med en nitrilaseaktivitet; eller (b) en nukleinsyresekvens, der er fuldstændigt komplementær til (a).
2. Ekspressionskassette, vektor eller kloningsmedium indeholdende en nukleinsyre omfattende en sekvens som angivet i krav 1.
3. Transformeret celle omfattende (i) en nukleinsyre med en sekvens som angivet i krav 1 eller en ekspressionskassette, en vektor eller et kloningsmedium som angivet i krav 2; (ii) den transformerede celle af (i), hvor cellen er (a) en gramnegativ bakterie, en grampositiv bakterie eller en eukaryotisk monocellulær organisme; (b) en Escherichia coli; (c) en Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lacto-coccus cremoris eller en Bacillus subtilis; eller (d) en Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha eller en Aspergillus niger.
4. Transgen, ikke-human organisme indeholdende en sekvens som angivet i krav 1 eller en ekspressionskassette, en vektor eller et kloningsmedium som angivet i krav 2.
5. Isoleret, syntetisk eller rekombinant polypeptid indeholdende: (a) en sekvens, der har mindst 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% eller mere, eller 100% sekvensidentitet med SEQ ID NO:104, hvor polypeptidet har en nitrilaseaktivitet; eller (b) en aminosyre kodet af nukleinsyren ifølge krav 1 (a).
6. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5, hvor nitrilaseaktiviteten omfatter (a) hydrolyse af et nitril til en carboxylsyre; (b) hydrolyse af en cyanhydrindel eller en aminonitrildel af et molekyle, hvor molekylet eventuelt indeholder (S)-2-amino-4-phenyl-butansyre, eller molekylet indeholder en L-aminosyre, eller molekylet indeholder et næringsmiddeladditiv eller et farmaceutisk lægemiddel; eller (c) en enantio-selektiv nitrilaseaktivitet, hvor den enantio-selektive aktivitet omfatter dannelse af et chiralt alfa-hydroxysyremolekyle eller et chiralt aminosyre-molekyle ved katalyse af hydrolysen af et molekyle med en cyanhydrindel eller en aminonitrildel, hvor det dannede chirale molekyle eventuelt er en (fl)-enantiomer eller en (S)-enantiomer.
7. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et hydroxyglutarylnitril til dannelse af en (fl)-ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt enantio-selektivt hydrolyserer hydroxyglutarylnitrilet til dannelse af en (F?)-enantiomer (F?)-ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt danner et produkt med en enantiomerrenhed omfattende en ee på mindst 95%, 96%, 97%, 98% eller 99%, og hvor hydroxyglutarylnitrilet eventuelt indeholder 1,3-di-cyano-2-hydroxy-propan eller et hydroxyglutaronitil, eller hvor hydroxyglutaronitrilet eventuelt omfatter et 3-hydroxyglutaronitril.
8. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et hydroxyglutarylnitril til dannelse af en ethyl 4-cyano-3-hydroxysmørsyre, hvor polypeptidet eventuelt enantio-selektivt hydrolyserer hydroxyglutarylnitrilet til dannelse af en (S)-enantiomer (S)-ethyl-4-cyano-3-hydroxysmørsyre, og hvor polypeptidet eventuelt danner et produkt med en enantiomerrenhed omfattende en ee på 95%, 96%, 97%, 98% eller 99%.
9. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et mandelonitril til dannelse af en mandelsyre eller et mandelsyrederivat, hvor mandelsyren eventuelt omfatter (f?)-2-chlormandelsyre, hvor mandelsyren eventuelt omfatter en aromatisk ringsubstitution i ortho-, me-ta- eller para-stillingerne; et 1-naphthylderivat af (F?)-mandelsyre, et pyridylderi-vat af (F?)-mandelsyre eller thienylderivat af (F?)-mandelsyre eller en kombination deraf, hvor mandelsyren eventuelt omfatter (S)-methyl-benzylcyanid, og mandelo-nitrilet omfatter (S)-methoxy-benzylcyanid, eller hvor mandelsyren eventuelt omfatter en aromatisk ringsubstitution i ortho-, me-ta- eller para-stillingerne; et 1-naphthylderivat af (S)-mandelsyre, et pyridylderi-vat af (S)-mandelsyre eller thienylderivat af (S)-mandelsyre eller en kombination deraf.
10. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 eller krav 6, hvor nitrilaseaktiviteten omfatter hydrolyse af et phenyllactocyanonitril til dannelse af et (S)-phenyl-mælkesyrederivat eller et (F?)-phenyl-mælkesyrederivat.
11. Enzympræparat indeholdende et polypeptid som angivet i ethvert af kravene 5 til 10, hvor præparatet er et flydende eller tørt præparat.
12. Industriel fremgangsmåde omfattende anvendelse af det isolerede, syntetiske eller rekombinante polypeptid som angivet i ethvert af kravene 5 til 10 ved hydrolysen af et substrat med en cyanhydrindel eller en aminonitrildel til dannelse af en sammensætning indeholdende en alfa-hydroxysyre eller en aminosyre.
13. Industriel fremgangsmåde ifølge krav 12, hvor den industrielle fremgangsmåde yderligere omfatter: (i) fremstillingen af en farmaceutisk sammensætning indeholdende den dannede alfa-hydroxysyre eller aminosyre, (ii) fremstillingen af en kemisk forbindelse indeholdende den dannede alfa-hydroxysyre eller aminosyre, (iii) katalyse af nedbrydningen af et affaldsprodukt, hvor nedbrydningen omfatter hydrolyse af et substrat med en cyanhydrindel eller en aminonitrildel, (iv) fremstillingen af et lægemiddelmellemprodukt, hvor lægemiddelmellemproduktet omfatter den dannede alfa-hydroxysyre eller aminosyre, og hvor po-lypeptidet eventuelt anvendes til at hydrolysere et hydroxyglutarylnitril-substrat, (v) fremstillingen af et detergent, eller (vi) fremstillingen af et næringsmiddelprodukt.
14. Isoleret, syntetisk eller rekombinant polypeptid ifølge krav 5 kodet af en nukleinsyre udtrykt i en værtscelle, hvor værtscellen omfatter: (a) en gramnegativ bakterie, en grampositiv bakterie eller en eukaryotisk monocellulær organisme; (b) en Escherichia coli; (c) en Streptomyces diversa, Lactobacillus gasseri, Lactococcus lactis, Lacto-coccus cremoris eller en Bacillus subtilis; eller (d) en Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha eller en Aspergillus niger.
15. Fremgangsmåde til fremstilling af en carboxylsyre, omfattende hydrolyse af et nitril under anvendelse af det isolerede, syntetiske eller rekombinante polypeptid ifølge krav 5 eller krav 6 under vandige betingelser.
16. Polypeptid ifølge krav 5, men som mangler en signalsekvens.
17. Polypeptid ifølge krav 5, der yderligere omfatter en heterolog sekvens.
DK10189100.0T 2001-06-21 2002-05-15 Nitrilaser DK2327765T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30018901P 2001-06-21 2001-06-21
US30900601P 2001-07-30 2001-07-30
US35133602P 2002-01-22 2002-01-22
EP08075753A EP2039762A3 (en) 2001-06-21 2002-05-15 Nitralases

Publications (1)

Publication Number Publication Date
DK2327765T3 true DK2327765T3 (da) 2015-07-13

Family

ID=27404717

Family Applications (3)

Application Number Title Priority Date Filing Date
DK10190397.9T DK2327766T3 (da) 2001-06-21 2002-05-15 Nitrilaser
DK10189100.0T DK2327765T3 (da) 2001-06-21 2002-05-15 Nitrilaser
DK10190399.5T DK2327767T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10190397.9T DK2327766T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10190399.5T DK2327767T3 (da) 2001-06-21 2002-05-15 Nitrilaser

Country Status (6)

Country Link
EP (6) EP1578910A4 (da)
JP (2) JP4405258B2 (da)
AU (2) AU2006252258B2 (da)
CA (2) CA2677781C (da)
DK (3) DK2327766T3 (da)
WO (1) WO2003000840A2 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537762A (ja) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US20040005673A1 (en) 2001-06-29 2004-01-08 Kevin Jarrell System for manipulating nucleic acids
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US20040002147A1 (en) * 1999-12-29 2004-01-01 Desantis Grace Nitrilases
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
US7932064B2 (en) 2002-06-13 2011-04-26 Verenium Corporation Processes for making (R)-ethyl 4-cyano-3-hydroxybutyric acid
ATE435278T1 (de) 2003-02-27 2009-07-15 Basf Se Modifizierte nitrilasen und deren verwendung in verfahren zur herstellung von carbonsäuren
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7198926B2 (en) 2003-05-08 2007-04-03 E. I. Du Pont De Nemours And Company Preparation of (E)- and (Z)-2-methyl-2-butenoic acids
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
US7485423B2 (en) 2004-11-11 2009-02-03 Modular Genetics, Inc. Ladder assembly and system for generating diversity
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
WO2007094885A2 (en) * 2005-12-07 2007-08-23 Southern Methodist University Identification of a nitrilase from b. japonicum by rational genome mining and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
CN100500832C (zh) * 2006-04-29 2009-06-17 浙江工业大学 枯草芽孢杆菌zjb-063及其应用
KR20090073121A (ko) 2006-09-29 2009-07-02 노파르티스 아게 Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
WO2008106662A2 (en) * 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
KR20100005730A (ko) 2007-05-07 2010-01-15 노파르티스 아게 유기 화합물
EA017919B1 (ru) 2007-12-10 2013-04-30 Новартис Аг Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов
JP5165393B2 (ja) * 2008-01-10 2013-03-21 旭化成ケミカルズ株式会社 グリコール酸又はグリコール酸アンモニウムの製造方法
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EP2813227A1 (en) 2009-10-22 2014-12-17 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
GB201111637D0 (en) * 2011-07-07 2011-08-24 Waterford Inst Technology A process for producing amides and acids using a nitrile-metabolising enzyme
GB201111639D0 (en) * 2011-07-07 2011-08-24 Waterford Inst Technology A process for producing amides and acids using a nitrile-metabolising enzyme
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
CN102363775B (zh) * 2011-11-30 2014-04-02 重庆大学 一种纯化腈水解酶的方法
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
PL3134395T3 (pl) 2014-04-24 2018-07-31 Novartis Ag Pochodne pirazyny jako inhibitory 3-kinazy fosfatydyloinozytolu
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
CN104774825B (zh) * 2015-03-23 2017-11-07 浙江工业大学 腈水解酶突变体及其应用
CN108368033B (zh) * 2015-11-19 2021-05-04 Gsp作物科学有限公司 一种用于制备肟菌酯的方法
CN106854673B (zh) * 2016-12-23 2020-05-15 枣庄市杰诺生物酶有限公司 利用腈水解酶工程菌制备r-邻氯扁桃酸的方法
CN109111043B (zh) * 2018-09-16 2021-11-09 苏州渭中科技发展有限公司 一种高盐高cod废水的处理方法
CN113614242A (zh) * 2019-01-22 2021-11-05 巴斯夫欧洲公司 4-氰基苯甲酸或其盐的生产方法
EP3980121A1 (en) 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
PH12022550468A1 (en) 2019-08-28 2023-03-06 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US813998A (en) 1903-10-31 1906-02-27 Rail Joint Co Insulated rail-joint.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU7791991A (en) 1990-04-24 1991-11-11 Stratagene Methods for phenotype creation from multiple gene populations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
JP2676568B2 (ja) 1991-06-26 1997-11-17 日東化学工業株式会社 Ｒ（−）−マンデル酸およびその誘導体の製造法
US5241087A (en) 1992-03-09 1993-08-31 Bend Research, Inc. Enantiomeric enrichment of cyanohydrins
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5958672A (en) 1995-07-18 1999-09-28 Diversa Corporation Protein activity screening of clones having DNA from uncultivated microorganisms
US6030779A (en) 1995-07-18 2000-02-29 Diversa Corporation Screening for novel bioactivities
JPH0937788A (ja) 1995-07-31 1997-02-10 Nitto Chem Ind Co Ltd 新規なニトリラーゼ遺伝子
US5965408A (en) 1996-07-09 1999-10-12 Diversa Corporation Method of DNA reassembly by interrupting synthesis
US5939250A (en) 1995-12-07 1999-08-17 Diversa Corporation Production of enzymes having desired activities by mutagenesis
DE19848129A1 (de) 1998-10-19 2000-04-20 Basf Ag Verfahren zur Herstellung chiraler Carbonsäuren aus Nitrilen mit Hilfe einer Nitrilase oder Mikroorganismen, die ein Gen für die Nitrilase enthalten
DE19929365A1 (de) 1999-06-25 2000-12-28 Basf Lynx Bioscience Ag Teilsequenzen der Gene des Primär- und Sekundärmetabolismus aus Corynebacterium glutamicum und ihr Einsatz zur mikrobiellen Herstellung von Primär- und Sekundärmetaboliten
US7300775B2 (en) * 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
WO2001055074A1 (en) 2000-01-25 2001-08-02 Kaneka Corporation Process for producing optically active carboxylic acid substituted in 2-position
EP3011302B1 (en) 2013-06-21 2019-11-27 Bio-Rad Laboratories, Inc. Microfluidic system with fluid pickups

Also Published As

Publication number Publication date
AU2006252258B2 (en) 2010-07-22
EP2319919B1 (en) 2015-08-12
DK2327766T3 (da) 2016-03-07
EP2327767B1 (en) 2015-04-29
EP2327765B1 (en) 2015-04-01
JP2007252382A (ja) 2007-10-04
EP2327766B1 (en) 2015-12-02
AU2010212259B2 (en) 2012-11-29
AU2010212259A1 (en) 2010-09-02
JP2005509407A (ja) 2005-04-14
EP2327766A1 (en) 2011-06-01
CA2445046A1 (en) 2003-01-03
JP4405528B2 (ja) 2010-01-27
AU2006252258A1 (en) 2007-01-25
JP4405258B2 (ja) 2010-01-27
EP1578910A4 (en) 2008-06-04
EP2319919A1 (en) 2011-05-11
CA2445046C (en) 2009-11-24
CA2677781A1 (en) 2003-01-03
EP1578910A2 (en) 2005-09-28
WO2003000840A2 (en) 2003-01-03
EP2327765A1 (en) 2011-06-01
EP2327767A1 (en) 2011-06-01
EP2039762A3 (en) 2009-07-29
CA2677781C (en) 2013-01-29
EP2039762A2 (en) 2009-03-25
DK2327767T3 (da) 2015-07-27
WO2003000840A3 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
DK2327766T3 (da) Nitrilaser
CA2486062C (en) Nitrilases, nucleic acids encoding them and methods for making and using them
US9828594B2 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
US8334125B2 (en) Nucleic acids encoding nitrilases
EP2115153B1 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
US20040014195A1 (en) Nitrilases, nucleic acids encoding them and methods for making and using them
AU2002350008A1 (en) Nitrilases